This article is more than 5 years old. Information may no longer be current.

NAFLD trial enrolls patients to assess effect of Basis on metabolic factors

Elysium Health completed enrollment for a clinical trial designed to evaluate the efficacy of Basis, a combination of the company’s proprietary nicotinamide riboside and pterostilbene, on liver fat accumulation in adults with nonalcoholic fatty liver disease, according to a press release.

The formulation of Basis was designed to increase oxidized nicotinamide adenine dinucleotide (NAD+) levels — a cofactor central to metabolism — and activate NAD-dependent sirtuins, which also regulate important physiological processes like lipid metabolism.

“There is evidence to show that people with fat accumulating in their liver exhibit lower levels of hepatic NAD+ and a lower ratio of NAD+ [to reduced NAD or NADH],” Oliver Chen, MD, principal investigator from the Friedman School of Nutrition Science and Policy at Tufts University, said in the release. “With this study, we are examining whether increased circulating levels of NAD+ will result in an enhancement of cellular metabolism and an increase in oxidation of hepatic fat.”

The fully enrolled trial includes 111 healthy adults with nonalcoholic fatty liver disease aged between 18 years and 70 years. Investigators will randomly assign patients to treatment or placebo groups for a 26-week treatment course.

Elysium expects to complete the trial in April 2020.

Reference: www.elysiumhealth.com